Therefore, their altered expression in GBM and the therapeutic effectiveness of pharmacological inhibitors, observed in a wide range of cancers, including hematopoietic malignancies [13], neuroblastomas [14], breast cancer [15], and prostate cancer [16], have suggested BET proteins as promising targets for the treatment of GBM. This evidence concerns the gene DNER and cancer.